Disodium aurothiomalate has been used in the treatment of rheumatoid arthritis (RA) for more than 50 years but its mechanism of action remains unknown. It has recently been demonstrated that disodium aurothiomalate dissociates to form free thiomalate and protein-bound gold.' While the absorption and excretion of the gold moiety have been extensively investigated, similar information on the thiol ligand is totally lacking. We have recently developed a method which allows quantitation of the low levels of free thiomalate found in physiological fluids during treatment with disodium aurothiomalate. 2 The aim of this study was to determine whether plasma or urinary levels of free thiomalate, measured either after the initial injection or after prolonged therapy, correlated with either response to, or toxicity from, treatment with disodium aurothiomalate in patients with RA. The study was not designed to assess the value of gold salts in RA. Thus an untreated control group and a 'blind' observer were not indicated.
Patients and methods
Patients with definite or classical rheumatoid arthritis were admitted to the study if they failed to respond to simple analgesic or anti-inflammatory drugs. None had previously received gold or D-penicillamine, and none were currently receiving steroids. All Fig. 1 .
Free thiomalate was detected in the urine of all patients. Mean levels for the 24 h following injection are shown in Fig. 1 . On each occasion maximum excretion occurred during the first hour. The percentage of the total dose of aurothiomalate administered, excreted in the urine in 24 h as free thiomalate (expressed on a molar basis), ranged from 2-2 to 16*0% (mean 6-9 + 3.7%) on entry and from 1-2 to 7-3% (mean 4-7 + 1.9%) at six months.
Plasma levels of free thiomalate (measured as area under curve 0-4 h) were not related to body weight. Plasma free thiomalate levels and 24 h urinary free thiomalate excretion, both on entry and at six months, did not differ significantly between 'responders' and 'non-responders' (Fig. 2) . Similarly there was no difference in initial plasma and urinary free thiomalate levels between patients who subsequently developed toxic reactions and those who did not (Fig. 2) 
